Bob Desai | Vice President, Technical
PAREXEL International Corp

Bob Desai, Vice President, Technical, PAREXEL International Corp

Dr. Desai has 22 years of Global Oncology Clinical Development experience. He’s spent 11 years working with the Pharmaceutical Industry and 15 years working as a Principal Investigator. Dr. Desai has experience in all phases of oncology drug development (pre-clinical development, clinical trial management, Designing Phase 1 to Phase 3 clinical trials, post-launch marketing, post-approval studies, Regulatory Affairs, and GCP, Broad strategy development for compound). 
Prior to joining PAREXEL, Dr. Desai was the Senior Medical Director and Global Medical Lead at Astellas Oncology.  
Dr. Desai completed Medical School in Vadodara, India in 1986. He then completed Internal Medicine in 1989, and Hematology and Medical Oncology training completion in 1992. Dr. Desai received ECFMG certification with US Medical Licensing exam step 3 in 2007.


World Orphan Drug Congress USA 2018 - Conference Day Two @ 11:15

Orphan drug designations in an era of novel technologies including CAR-T-cell, stem cells and gene therapy

  • Case studies of recent FDA approvals with orphan drug designation
  • Challenges for the newer modality of therapies such as CAR-T intended to treat diseases with higher prevalence including cancers 
  • Different requirements and challenges faced by pharmaceutical companies to obtain global orphan drug designations 

back to speakers